Replimune Group

REPLIMUNE GROUP INC

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Tesla Inc.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

DOGZ

MAZE

OPCH

ORIS

PLRX

REPL

SMTC

TSLA

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Wall Street

CENX

FENC

MBOT

MGOL

MYNA

PNBK

PSIG

SATL

SLDB

STBX

YOSH

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

wall street chart shutter2

Equities

Eurozone

Commodities

Intraday Update

New Oriental Education & Technology Group

EOLS

FTAI

GOEV

HSDT

SCHW

Nasdaq Jumps 100 Points; Charles Schwab Profit Beats Estimates

Replimune Group Inc

REPLENISH NUTRIENTS HLDG by REPLENISH NUTRIENTS HLDG CORP.

Replenish Nutrients Holding Corp

REPLICEL LIFE SCIENCE ORD by RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc

Repligen Corp

Reply SpA

Health Care

Press Releases

General

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Announces Proposed Public Offering

Replimune Announces Pricing of Upsized Public Offering

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

Earnings

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Replimune Announces Inducement Grants Under Nasdaq  Listing Rule 5635(c)(4)

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

CareDx

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

GRAIL

Gyre Therapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

LENZ Therapeutics

MeiraGTx Hldgs

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Organogenesis Holdings

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Vir Biotechnology

Xencor

Zymeworks

JP Morgan

HC Wainwright & Co.

BMO Capital

Jefferies

Roth MKM

Comments

Replimune Group

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga